Glaukos Corporation

GKOSleader

Glaukos invented the MIGS (micro-invasive glaucoma surgery) category with iStent, and is expanding into sustained-release drug delivery (iDose TR) and keratoconus treatment (Photrexa).

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($370M)

Data statis (memuat keuangan langsung…)

MIGS & Corneal Health (US) (72%)

International (28%)

Komposisi segmen dan pelanggan utama

Detail produk

iStent (MIGS)52%

World's smallest FDA-approved medical device — tiny titanium stent implanted in eye during cataract surgery to lower IOP in glaucoma.

iDose TR (Sustained-release)25%

Travoprost intracameral implant providing 18-month drug delivery for glaucoma — no daily eye drops needed.

Photrexa (Corneal Cross-linking)23%

FDA-approved drug for keratoconus cross-linking — combined with UV light to halt corneal thinning.

Hubungan Rantai Pasok

Pesaing

alcon

MIGS device market

Dampak: major

Mitra

Abbott Laboratories

Cataract procedure integration

Dampak: significant

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Glaukos Corporation.

Info Perusahaan

Kantor Pusat

San Clemente, California, USA

Didirikan

1998

Karyawan

1,400

Situs Web

glaukos.com

Gambaran umum sektor — 헬스케어

Berita sektor